Effects of multimorbidity and polypharmacy on blood pressure target attainment in patients with hypertension-Reference-Cited by-同舟云学术

Effects of multimorbidity and polypharmacy on blood pressure target attainment in patients with hypertension

Published:2024-07-29 Issue:3 Volume:6 Page:128-134
ISSN:2687-4245
Container-title:Turkish Journal of Internal Medicine
language:
Short-container-title:

Author:

Güven Alper Tuna¹^ORCID,Hocanın Naciye¹^ORCID,Ambarkütükoğlu Arif Emre¹^ORCID,Kaplan Ceren¹^ORCID,Çaylayık Tuana¹^ORCID,Ardebili Yasemen Arzani¹^ORCID,Özden Elif¹^ORCID,Karasüleymanoğlu Sevcan¹^ORCID,Şahin Zülal¹^ORCID

Affiliation:

1. BASKENT UNIVERSITY, FACULTY OF MEDICINE

Abstract

Background Hypertension prevalence increases with age, as well as polypharmacy and multimorbidity (P&M), which are the use of multiple medications and the presence of multiple chronic diseases, respectively. Whether P&M affects attaining blood pressure (BP) goals is not clear. Methods Hypertensive patients in the general internal medicine outpatient clinic were evaluated retrospectively. Data regarding age, gender, comorbidities, medications, office BP (OBP), home BP (HBP), and ambulatory BP (ABP) were obtained. Having two or more diseases was classified as multimorbidity, whereas using five or more drugs was classified as polypharmacy. OBP

Publisher

Turkish Journal of Internal Medicine

Reference23 articles.

1. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019 Jul;74(1):120-31. doi: 10.1053/j.ajkd.2018.12.044.

2. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, Williams KA. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2020 Feb;43(2):99-107. doi: 10.1002/clc.23303.

3. Tsai WC, Wu HY, Peng YS, Yang JY, Chen HY, Chiu YL, Hsu SP, Ko MJ, Pai MF, Tu YK, Hung KY, Chien KL. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: A systematic review and meta-analysis. JAMA Intern Med. 2017 Jun 1;177(6):792-9. doi: 10.1001/jamainternmed.2017.0197.

4. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3.

5. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480.